HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Traditional Chinese Medicine

829.472

-6.193-0.74%

Number of Gainers:5

Number of Losers:4

Number of Flat:2

PE:- -

High:839.227

Open:835.423

Low:825.182

Close:835.665

Loading ...

China Traditional Chinese Medicine Holdings Co. Limited Conducted Annual General Meeting

China Traditional Chinese Medicine Holdings Co. Announces NMPA Acceptance of New Drug Application for Yushuda Tablets, Initiating Regulatory Review

China Traditional Chinese Medicine - Nmpa Acceptance of New Drug Application of Yushuda Tablets

THOMSON REUTERS

Consun Pharmaceutical Files Disclosure to HKEX: Repurchases 1,462,000 Shares for HKD 1,506,860

China Traditional Chinese Medicine Holdings Co. Limited Announces Board Committee Restructuring, Welcomes New Members

Consun Pharmaceutical Group Ltd. Announces Changes in Nomination Committee Composition

Consun Pharmaceutical Group Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 1,227,000 Shares for HKD 241,780

Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S

Consun Pharmaceutical Group Ltd. Files Next Day Disclosure with HKEX Announcing Repurchase of 350,000 Shares for HKD 3,930,185

JBM (Healthcare) Ltd. Announces Acquisition of Target Group to Enhance Chinese Medicine Portfolio

JBM (Healthcare) Ltd - to Acquire Kenford Medical Group at HK$38 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1606/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","market":"HK","secType":"PLATE","nameCN":"Traditional Chinese Medicine","latestPrice":829.47205,"timestamp":1751011731245,"preClose":835.6649,"halted":0,"volume":99046159,"delay":0,"changeRate":-0.007411,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-6.192871,"latestTime":"06-27 16:00:00","open":835.42334,"high":839.227,"low":825.18243,"amount":351352996,"amplitude":0.016806,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751247000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1750987800000,1750996800000],[1751000400000,1751011200000]],"pbRate":0.940768,"peRate":14.894213,"turnoverRate":0.006562,"increases":5,"decrements":4,"flats":2,"marketCap":86013056240,"floatMarketCap":58309716720},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","high":839.227,"amplitude":0.016806,"preClose":835.6649,"low":825.18243,"pbRate":"0.940768","latestPrice":829.47205,"volume":99046159,"delay":0,"open":835.42334,"prevYearClose":739.0471,"prevWeekClose":804.343,"prevMonthClose":762.763,"prevQuarterClose":689.055,"fiveDayClose":804.343,"twentyDayClose":762.763,"sixtyDayClose":718.463,"secType":"PLATE","market":"HK","turnoverRate":0.006562,"peRate":14.894213,"marketCap":86013056240,"floatMarketCap":58309716720,"timestamp":1751011731245,"nameCN":"Traditional Chinese Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1606\",,,,undefined,":{"bkCode":"BK1606","up":5,"down":4,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1606\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546106307","title":"China Traditional Chinese Medicine Holdings Co. Limited Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546106307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546106307?lang=en_us&edition=fundamental","pubTime":"2025-06-27 19:03","pubTimestamp":1751022228,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited held its Annual General Meeting on 27 June 2025. During the meeting, several proposals were reviewed, including the re-election of Mr. HUANG Hao, Mr. YU Tze Shan Hailson, and Mr. QIN Ling as directors of the company. All proposals were approved by the shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL980Zv6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570","BK1191","BK1515","BK1606"],"gpt_icon":0},{"id":"2546421119","title":"China Traditional Chinese Medicine Holdings Co. Announces NMPA Acceptance of New Drug Application for Yushuda Tablets, Initiating Regulatory Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2546421119","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546421119?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:50","pubTimestamp":1750848605,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Announces NMPA Acceptance of New Drug Application for Yushuda Tablets, Initiating Regulatory Review. China Traditional Chinese Medicine Holdings Co. Limited has announced that the National Medical Products Administration  of China has accepted the new drug application for Yushuda Tablets, a Class 1.1 innovative traditional Chinese medicine developed by its subsidiary, Sinopharm Group Tongjitang  Pharmaceutical Co., Ltd. The acceptance marks the start of a series of regulatory review procedures, including technical evaluation and on-site inspection. Yushuda Tablets have shown significant efficacy in treating symptoms associated with qi stagnation and mild-to-moderate depression. While this is a promising development, the timeline for final approval remains uncertain, and shareholders are advised to exercise caution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL7TXdX5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU1115378108.SGD","BK1606","BK1515","00570","BK1500","01099","LU0640798160.USD","BK1197"],"gpt_icon":0},{"id":"2546211944","title":"China Traditional Chinese Medicine  -  Nmpa Acceptance of New Drug Application of Yushuda Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2546211944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546211944?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:47","pubTimestamp":1750848464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nFWN3SS06S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","BK1515","BK1191","00570"],"gpt_icon":0},{"id":"2545125404","title":"Consun Pharmaceutical Files Disclosure to HKEX: Repurchases 1,462,000 Shares for HKD 1,506,860","url":"https://stock-news.laohu8.com/highlight/detail?id=2545125404","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545125404?lang=en_us&edition=fundamental","pubTime":"2025-06-23 21:09","pubTimestamp":1750684177,"startTime":"0","endTime":"0","summary":"Consun Pharmaceutical Group Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, reporting the repurchase of 135,000 ordinary shares. The aggregate price paid for the repurchase was HKD 1,506,860.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Consun Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL22htRT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","01681","BK1191"],"gpt_icon":0},{"id":"2544247251","title":"China Traditional Chinese Medicine Holdings Co. Limited Announces Board Committee Restructuring, Welcomes New Members","url":"https://stock-news.laohu8.com/highlight/detail?id=2544247251","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544247251?lang=en_us&edition=fundamental","pubTime":"2025-06-20 20:02","pubTimestamp":1750420937,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited announced changes to its board committees effective June 20, 2025. Ms. Xu Jinghui, a non-executive director, will join the nomination committee, leaving the audit committee. Mr. Zu Jing, another non-executive director, will move to the audit committee, departing from the strategic committee. Additionally, Mr. Liu Haijian, also a non-executive director, will join the strategic committee, exiting the nomination committee. The company aims to enhance the diversity and governance of its board with these adjustments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief on J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL7PlZMX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1515","BK1191","00570"],"gpt_icon":0},{"id":"2544009149","title":"Consun Pharmaceutical Group Ltd. Announces Changes in Nomination Committee Composition","url":"https://stock-news.laohu8.com/highlight/detail?id=2544009149","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544009149?lang=en_us&edition=fundamental","pubTime":"2025-06-20 16:35","pubTimestamp":1750408514,"startTime":"0","endTime":"0","summary":"Consun Pharmaceutical Group Ltd. has announced changes to the composition of its Nomination Committee effective 20 June 2025. Mr. An Meng, the chairman of the Board, is no longer a member of the committee. Dr. Zhang Lihua, a non-executive Director, has been appointed to the committee. The committee will now consist of Professor Li Yikai , Dr. Zhang Lihua, and Mr. Duan Weiwu.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Consun Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLsZJvP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01681","BK1606"],"gpt_icon":0},{"id":"2544150087","title":"Consun Pharmaceutical Group Ltd. Files Next Day Disclosure to HKEX Announcing Repurchase of 1,227,000 Shares for HKD 241,780","url":"https://stock-news.laohu8.com/highlight/detail?id=2544150087","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544150087?lang=en_us&edition=fundamental","pubTime":"2025-06-19 17:54","pubTimestamp":1750326865,"startTime":"0","endTime":"0","summary":"Consun Pharmaceutical Group Ltd. filed a next day disclosure return to the Hong Kong Stock Exchange, reporting the repurchase of 1,227,000 ordinary shares at an aggregate price of HKD 241,780. The repurchase was carried out as per the mandate authorized on 22 May 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Consun Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nNDL9qJ1L0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681","BK1606","BK1191"],"gpt_icon":0},{"id":"2544090939","title":"Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S","url":"https://stock-news.laohu8.com/highlight/detail?id=2544090939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544090939?lang=en_us&edition=fundamental","pubTime":"2025-06-17 12:06","pubTimestamp":1750133187,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration  to initiate clinical trials for its novel antibody-drug conjugate , BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL9pqK1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","06955","02186","BK1606","BK1161"],"gpt_icon":0},{"id":"2543679636","title":"Consun Pharmaceutical Group Ltd. Files Next Day Disclosure with HKEX Announcing Repurchase of 350,000 Shares for HKD 3,930,185","url":"https://stock-news.laohu8.com/highlight/detail?id=2543679636","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543679636?lang=en_us&edition=fundamental","pubTime":"2025-06-16 18:46","pubTimestamp":1750070816,"startTime":"0","endTime":"0","summary":"Consun Pharmaceutical Group Ltd. Files Next Day Disclosure with HKEX Announcing Repurchase of 350,000 Shares for HKD 3,930,185. Consun Pharmaceutical Group Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange . The company repurchased a total of 350,000 shares at an aggregate price of HKD 3,930,185. The repurchased shares are intended for cancellation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Consun Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL6L330M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","01681","BK1191"],"gpt_icon":0},{"id":"2543675926","title":"JBM (Healthcare) Ltd. Announces Acquisition of Target Group to Enhance Chinese Medicine Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2543675926","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543675926?lang=en_us&edition=fundamental","pubTime":"2025-06-16 18:08","pubTimestamp":1750068496,"startTime":"0","endTime":"0","summary":"JBM  Ltd. announced on June 16, 2025, that its indirect wholly-owned subsidiary has entered into a sale and purchase agreement to acquire the entire issued shares of Kenford Medical Group Company Limited. The acquisition includes Kenford Medical Group and its subsidiaries, which operate a network of over 20 TCM consultancy clinics across Hong Kong. These clinics are strategically positioned in major residential estates and shopping malls, offering convenient access to high-quality traditional Chinese medicine services. The seller, Ever Development Holdings Limited, is a company based in the British Virgin Islands. The acquisition is part of JBM  Ltd.'s strategy to expand its healthcare services portfolio in Hong Kong.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL27RSvZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","02161"],"gpt_icon":0},{"id":"2543759846","title":"JBM (Healthcare) Ltd -  to Acquire  Kenford Medical Group at HK$38 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2543759846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543759846?lang=en_us&edition=fundamental","pubTime":"2025-06-16 18:06","pubTimestamp":1750068410,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nFWN3SG0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","CBDY","BK1606","02161","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}